Sanofi (SNY) Receives Average Rating of “Hold” from Analysts
Sanofi (NYSE:SNY) has earned an average rating of “Hold” from the sixteen brokerages that are currently covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and five have issued a buy rating on the company. The average 1 year price target among brokerages that have covered the stock in the last year is $55.00.
Several research firms recently weighed in on SNY. J P Morgan Chase & Co raised shares of Sanofi from an “underperform” rating to a “neutral” rating in a research note on Tuesday, April 11th. BidaskClub cut shares of Sanofi from a “buy” rating to a “hold” rating in a research note on Friday, June 9th. Argus raised their target price on shares of Sanofi from $50.00 to $55.00 and gave the company a “buy” rating in a research note on Friday, June 9th. Zacks Investment Research raised shares of Sanofi from a “hold” rating to a “buy” rating and set a $55.00 target price for the company in a research note on Friday, June 2nd. Finally, Berenberg Bank cut shares of Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, May 11th.
Institutional investors have recently added to or reduced their stakes in the company. Russell Investments Group Ltd. bought a new position in Sanofi during the fourth quarter worth approximately $1,606,000. Guggenheim Capital LLC boosted its position in Sanofi by 1.5% in the fourth quarter. Guggenheim Capital LLC now owns 21,558 shares of the company’s stock worth $872,000 after buying an additional 311 shares during the period. Migdal Insurance & Financial Holdings Ltd. bought a new position in Sanofi during the fourth quarter worth approximately $483,000. Philadelphia Trust Co. boosted its position in Sanofi by 7.6% in the fourth quarter. Philadelphia Trust Co. now owns 49,300 shares of the company’s stock worth $1,994,000 after buying an additional 3,500 shares during the period. Finally, Beacon Financial Group boosted its position in Sanofi by 0.9% in the first quarter. Beacon Financial Group now owns 79,526 shares of the company’s stock worth $3,566,000 after buying an additional 725 shares during the period. 9.84% of the stock is owned by hedge funds and other institutional investors.
Sanofi (NYSE:SNY) traded down 0.73% during mid-day trading on Friday, hitting $47.71. 941,576 shares of the company traded hands. Sanofi has a one year low of $36.81 and a one year high of $50.24. The stock has a market capitalization of $120.49 billion, a price-to-earnings ratio of 11.56 and a beta of 0.89. The company’s 50-day moving average is $48.37 and its 200-day moving average is $45.39.
Sanofi (NYSE:SNY) last released its earnings results on Friday, April 28th. The company reported $0.76 earnings per share for the quarter, beating the consensus estimate of $0.73 by $0.03. Sanofi had a net margin of 26.55% and a return on equity of 25.89%. The business had revenue of $8.65 billion during the quarter, compared to analysts’ expectations of $8.40 billion. Sanofi’s quarterly revenue was up 1.2% compared to the same quarter last year. Analysts predict that Sanofi will post $3.20 EPS for the current year.
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.